Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 1, 2017

BioPharm International

  • BioPharm International-11-01-2017
  • Volume 30
  • Issue 11

Analytical Data System Update

An updated version of Shimadzu’s LabSolutions analytical data system features an operating environment for complete data management and security in networked laboratories.

An updated version of Shimadzu’s LabSolutions analytical data system incorporates additional functions to comply with data integrity regulations, and to support development and quality inspection procedures. The software features an operating environment for complete data management and security in networked laboratories and can be used with traditional peak integration methods. Users can switch between traditional and new peak integration methods during analysis, allowing the selection of an appropriate peak integration method for the circumstance. This includes selecting a traditional method for compatibility with past data.

A peak integration algorithm in the software can quantify overlapping peaks more accurately, the company reports. The intelligent peak deconvolution analysis (i-PDeA II), which uses analyte UV spectral information obtained by the PDA detector, has been improved and can be used to show data traces for single components more accurately than with the conventional peak purity method, enabling accurate quantitative values, even for co-eluting peaks. 

Shimadzu


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.